Danske Bank A S Has $12.02 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Danske Bank A S lifted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 133,717 shares of the medical equipment provider’s stock after buying an additional 7,400 shares during the period. Danske Bank A S’s holdings in Zimmer Biomet were worth $12,024,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ZBH. Brighton Jones LLC acquired a new stake in Zimmer Biomet during the fourth quarter valued at $204,000. Sivia Capital Partners LLC acquired a new stake in Zimmer Biomet during the second quarter valued at $232,000. United Bank boosted its position in Zimmer Biomet by 10.7% during the second quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock valued at $1,085,000 after purchasing an additional 1,153 shares during the last quarter. Federated Hermes Inc. boosted its position in Zimmer Biomet by 129.2% during the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock valued at $194,000 after purchasing an additional 1,202 shares during the last quarter. Finally, Cerity Partners LLC boosted its position in Zimmer Biomet by 93.6% during the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock valued at $7,004,000 after purchasing an additional 37,116 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $83.07 on Monday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.83 and a fifty-two week high of $108.29. The business has a 50-day moving average of $92.53 and a two-hundred day moving average of $92.68. The stock has a market capitalization of $16.08 billion, a P/E ratio of 21.58, a P/E/G ratio of 1.91 and a beta of 0.48. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. During the same quarter in the previous year, the firm earned $1.81 earnings per share. The business’s quarterly revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were given a $0.24 dividend. The ex-dividend date of this dividend was Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.2%. Zimmer Biomet’s payout ratio is currently 24.94%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. JPMorgan Chase & Co. reduced their price objective on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research report on Wednesday, April 29th. Wells Fargo & Company reduced their price objective on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 29th. TD Cowen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, February 10th. Finally, The Goldman Sachs Group cut Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price target for the company. in a research report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $102.43.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares in the company, valued at approximately $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.28% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.